Influence of diet and nutritional status on drug metabolism

Clinical Pharmacokinetics

Volumn 31, Issue 1, 1996, Pages 47-64

  Walter Sack, Inge ^b   Klotz, Ulrich ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHENAZONE; AURANTIIN; BENZPHETAMINE; COUMARIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 ISOENZYME; DRUG METABOLIZING ENZYME; ETHOXYRESORUFIN; FELODIPINE; FLAVANOID; FOOD ADDITIVE; GLUCURONOSYLTRANSFERASE; HEXOBARBITAL; IFOSFAMIDE; INDOLE; NIFEDIPINE; NITRENDIPINE; OXAZEPAM; PARACETAMOL; PHENACETIN; PHENAZONE; PHENOBARBITAL; PHENYTOIN; POLYCYCLIC HYDROCARBON; PROPRANOLOL; PURINE; THEOPHYLLINE; UNINDEXED DRUG; VITAMIN; WARFARIN;

COOKING; DIET; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG OXIDATION; FOOD INTAKE; FOOD PROCESSING; FRUIT JUICE; HUMAN; LIVER METABOLISM; MALNUTRITION; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; REVIEW; STARVATION; VEGETABLE;

EID: 0029978949     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199631010-00004     Document Type: Review

References (155)

1. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994; 26: 144-60
2. Nelson DR, Kamataki T, Waxman DJ, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993; 12: 1-51
3. Brøsen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990; 18: 220-39
4. Pelkonen O, Breimer DD. Role of environmental factors in the pharmacokinetics of drugs: considerations with respect to animal models, P-450 enzymes and probe drugs. In: Welling PG, Balant LP, editors. Handbook of experimental pharmacology. Vol. 110. Berlin/Heidelberg: Springer, 1994: 269-332
5. Spatzenegger M, Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 1995; 27: 397-417
6. Shimada F, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-23
7. Brockmöller J, Roots I. Assessment of liver metabolic function: clinical implications. Clin Pharmacokinet 1994; 27: 216-48
8. Kroemer HK, Klotz U. Glucuronidation of drugs: a re-evaluation of the pharmacological significance of the conjugates and modulating factors. Clin Pharmacokinet 1992; 23: 293-310
9. Klotz U. Pathophysiological and disease-induced changes in distribution volume: pharmacokinetic implications. Clin Pharmacokinet 1976; 1: 204-18
10. Vesell ES. The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther 1979; 26: 275-86
11. Vesell ES. The model drug approach in clinical pharmacology. Clin Pharmacol Ther 1991; 50: 239-48
12. Eichelbaum M, Ochs HR, Robertz GM, et al. Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration. Arzneimittel Forschung 1982; 32: 575-8
13. Engel G, Hofmann U, Heidemann H, et al. Antipyrine as a probe for human oxidative drug metabolism: part 1. Identification of the cytochrome P450 enzymes catalyzing 4-hydroxy-, 3-hydromethyl- and norantipyrine formation. Clin Pharmacol Ther 1996; 59 (5): in press
14. Alvares AP. Interactions between environmental chemicals and drug biotransformation in man. Clin Pharmacokinel 1978; 3: 462-77
15. Alvares AP, Pantuck EJ, Anderson KE, et al. Regulation of drug metabolism in man by environmental factors. Drug Metab Rev 1979; 9: 185-205
16. Krishnaswamy K. Drug metabolism and pharmacokinetics in malnutrition. TIPS 1983 Jul: 295-9
17. Vesell ES. Complex effects of diet on drug disposition. Clin Pharmacol Ther 1984; 36: 285-96
18. Bidlack WR, Smith CH. The effect of nutritional factors on hepatic drug and toxicant metabolism. J Am Diet Assoc 1984; 84: 892-98
19. Buchanan N. Effect of protein-energy malnutrition on drug metabolism in man. World Rev Nutr Diet 1984; 43: 129-39
20. Roncucci R, Verry M, Jeanniot JP. Interactions between nutrition, food and drugs in man. World Rev Nutr Diet 1984; 43: 140-52
21. Welling P. Nutrient effects on drug metabolism and action in the elderly. Drug Nutr Interact 1985; 4: 173-207
22. Walter-Sack I. The influence of nutrition on the systemic availability of drugs: part II. Drug metabolism and renal excretion. Klin Wochenschr 1987; 65: 1062-72
23. Anderson KE. Influences of diet and nutrition on clinical pharmacokinetics. Clin Pharmacokinet 1988; 14: 325-46
24. Roberts J, Tumer N. Age and diet effects on drug action. Pharmacol Ther 1988; 37: 111-49
25. Pfeifer S. Pharmakokinetische Interaktionen zwischen Nahrungs-und Arzneimitteln. Pharm Zeitschr 1995; 2: 125-31
26. Anderson KE, Kappas A. Dietary regulation of cytochrome P450. Annu Rev Nutr 1991; 11: 141-67
27. Nestle M. Nutrition in clinical practice. Greenbrae (CA): Jones Medical Publications, 1985
28. Zöllner N. Feststellung des Ernährungszustandes. In: Kühn HA, Zöllner N, editors. Allgemeine und klinische Ernährungslehre. Bd II, Teil I. Stuttgart: Georg Thieme Verlag, 1978: 1-7
29. Branch RA, Shand DG. Propranolol disposition in chronic liver disease: a physiological approach. In: Gibaldi M, Prescott L, editors. Handbook of clinical pharmacokinetics. Sydney: ADIS Health Science Press, 1983
30. Liedholm H, Melander A. Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation. Clin Pharmacol Ther 1986; 40: 29-36
31. McLean AJ, Isbister C, Bobik A, et al. Reduction of first pass hepatic clearance of propranolol by food. Clin Pharmacol Ther 1981; 30: 31-4
32. Melander A, Danielson K, Scherstén B, et al. Enhancement of the bioavailability of propranolol and metoprolol by food. Clin Pharmacol Ther 1977; 22: 108-12
33. Olanoff LS, Walle T, Cowart TD, et al. Foods effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. Clin Pharmacol Ther 1986; 40: 408-14
34. Walle T, Fagan TC, Walle K, et al. Food-induced increase in propranolol bioavailability - relationship to protein and effects on metabolites. Clin Pharmacol Ther 1981; 30: 790-5
35. Feely J, Nadeau J, Wood AJJ. Effects of feeding on the systemic clearance of indocyanine green and propranolol blood concentrations and plasma binding. Br J Clin Pharmacol 1983; 15: 383-5
36. Melander A, McLean A. Influence of food intake on presystemic clearance of drugs. Clin Pharmacokinet 1983; 8: 286-96
37. Schneck DW, Vary JE. Mechanism by which hydralazine increases propranolol bioavailability. Clin Pharmacol Ther 1984; 35: 447-53
38. Svensson CK, Edwards DJ, Muriello PM, et al. Effect of food on hepatic blood flow: implications in the 'food effect' phenomenon. Clin Pharmacol Ther 1983; 316-23
39. Svensson CK, Muriello PM, Barde SH, et al. Effect of carbohydrates on estimated hepatic blood flow. Clin Pharmacol Ther 1984; 35: 660-5
40. Svensson CK, Cumella JC, Tronolone M, et al. Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. Clin Pharmacol Ther 1985; 37: 464-8
41. Daneshmend TK, Jackson L, Roberts CJC. Physiological and pharmacological variability in estimated hepatic blood flow in man. Br J Clin Pharmacol 1981; 11: 491-6
42. Griensven van JMT, Burggraaf KJ, Gerloff J, et al. Effects of changing liver blood flow by exercise and food on kinetics and dynamics of saruplase. Clin Pharmacol Ther 1995; 57: 381-9
43. Sabbá C, Ferraioli G, Genecin P, et al. Evaluation of postprandial hyperemia in superior mesenteric artery and portal vein in healthy and cirrhotic humans: an operator-blind echo-doppler study. Hepatology 1991; 13: 714-8
44. Sabbá C, Ferraioli G, Buonamico P, et al. A randomized study of propranolol on postprandial portal hyperemia in cirrhotic patients. Gastroenterology 1992; 102: 1009-16
45. Byrne AJ, McNeil JJ, Harrison PM, et al. Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rates as a determinant of presystemic drug interactions. Br J Clin Pharmacol 1984; 17: 45S-50S
46. Daneshmend TK, Roberts CJC. The Influence of food on the oral and the intravenous pharmacokinetics of a high clearance drug: a study with labetalol. Br J Clin Pharmacol 1982; 14: 73-8
47. Elvin AT, Cole AFD, Pieper JA, et al. Effect of food on lidocaine kinetics: mechanism of food-related alteration in high intrinsic clearance drug elimination. Clin Pharmacol Ther 1981; 30: 455-60
48. Ke J, Tam YK, Koo WWK, et al. Lack of acute effect on lidocaine pharmacokinetics from parenteral nutrition. Ther Drug Monit 1990; 12: 157-62
49. Eichelbaum M, Somogyi A. Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Eur J Clin Pharmacol 1984; 26: 47-53
50. Woodcock BG, Kraemer N, Rietbrock N. Effect of a high protein meal on the bioavailability of verapamil. Br J Clin Pharmacol 1986; 21: 337-8
51. Conway EL, Phillips PA, Drummer OH, et al. Influence of food on the bioavailability of a sustained-release verapamil preparation. J Pharm Sci 1990; 79: 228-31
52. Overdick HWPM, Merkus FWHM. Influence of food on the bioavailability of spironolactone. Clin Pharmacol Ther 1986; 40: 531-6
53. Melander A, Danielson K, Hanson A, et al. Enhancement of hydralazine bioavailability by food. Clin Pharmacol Ther 1977; 22: 104-7
54. Melander A. Influence of food on the bioavailability of drugs. Clin Pharmacokinet 1978; 3: 337-51
55. Liedholm H, Wahlin-Boll E, Hanson A, et al. Influence of food on the bioavailability of 'real' and 'apparent' hydralazine from conventional and slow-release preparations. Drug Nutr Interact 1982; 1: 293-302
56. Shepherd AMM, Irvine NA, Ludden TM. Effect of food on hydralazine levels and response in hypertension. Clin Pharmacol Ther 1984; 36: 14-8
57. Melander A, Liedholm H, McLean A. Concomitant food intake does enhance the bioavailability and the effect of hydralazine. Clin Pharmacol Ther 1985; 38: 475
58. Waller-Sack I. The influence of nutrition on the systemic availability of drugs: part I. Drug absorption. Klin Wochenschr 1987; 65: 927-35
59. Walter-Sack I. The significance of nutrition for the biopharmaceutical characteristics of oral extended release preparations and enteric coated dosage forms. In: Gundert-Remy U, Möller H, editors. Oral controlled release products. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 1990: 117-37
60. Walter-Sack I. What is 'fasting' drug administration? On the role of gastric motility in drug absorption. Eur J Clin Pharmacol 1992; 11-3
61. Ferry JJ, Horvath AM, Sedman AJ, et al. Influence of food on the pharmacokinetics of quinapril and its active diacid metabolite, CI-029. J Clin Pharmacol 1987; 27: 397-9
62. Lecocq B, Funck-Brentano C, Lecocq V, et al. Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum. Clin Pharmacol Ther 1990, 47: 397-402
63. Challenor VF, Waller DG, Gruchy BS, et al. Food and nifedipine kinetics. Br J Clin Pharmacol 1987; 23: 248-9
64. Melander A, Lalka D, McLean A. Influence of food intake on presystemic metabolism of drugs. Pharmacol Ther 1988, 38: 253-67
65. Fagan TC, Walle T, Oexmann MJ, et al. Increased clearance of propranolol and theophylline by high-protein compared with high-carbohydrate diet. Clin Pharmacol Ther 1987; 41: 402-6
66. Gupta SK, Bend LZ. High-fat meals increase the clearance of cyclosporine. Pharm Res 1990, 7: 46-8
67. Bianchine JR, Shaw GM. Clinical pharmacokinetics of levodopa in Parkinson's disease. Clin Pharmacokinet 1976; 1: 313-38
68. Cedarbaum JM. Clinical pharmacokinetics of anti-parkinsonian drug. Clin Pharmacokinet 1987; 13: 141-78
69. Krishnaswamy K, Kalamegham R, Naidu NA. Dietary influences on the kinetics of antipyrine and aminopyrine in human subjects. Br J Clin Pharmacol 1984; 17; 139-46
70. Alvarez AP, Anderson KE, Conney AH, et al. Interactions between nutritional factors and drug biotransformation in man. Proc Natl Acad Sci USA 1976; 73: 2501-4
71. Anderson KE, Conney AH, Kappas A. Nutrition and oxidative drug metabolism in man: relative influence of dietary lipids, carbohydrate and protein. Clin Pharmacol Ther 1979; 26: 493-501
72. Kappas A, Anderson KE, Conney AH, et al. Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. Clin Pharmacol Ther 1976; 20: 643-53
73. Wissel PS, Denke M, Inturrisi CE. A comparison of the effects of a macrobiotic diet and a Western diet on drug metabolism and plasma lipids in man. Eur J Clin Pharmacol 1987; 33: 403-7
74. Hamberg O, Ovesen L, Dorfeldt A, et al. The effect of dietary energy and protein deficiency on drug metabolism. Eur J Clin Pharmacol 1990; 38: 567-70
75. Burgess P, Hall RJ, Bateman DN, et al. Antipyrine clearance during total parenteral nutrition in man. Br J Clin Pharmacol 1985; 20: 253P-4P
76. Burgess P, Hall RI, Bateman DN, et al. The effect of total parenteral nutrition on hepatic drug oxidation. JPEN 1987; 11: 540-3
77. Pantuck EJ, Pantuck CB, Weissman C, et al. Stimulation of oxidative drug metabolism by parenteral refeeding of nutritionally depleted patients. Gastroenterology 1985; 89: 241-5
78. Pantuck EJ, Pantuck CB, Weissman C, et al. Effects of parenteral nutritional regimens on oxidative drug metabolism. Anesthesiology 1984; 60: 534-6
79. Pantuck FJ, Weissman C, Pantuck CB, et al. Effects of parenteral amino acid nutritional regimens on oxidative and conjugative drug metabolism. Anesth Analg 1989; 69: 727-31
80. Tranvouez JL, Lerebours E, Chretien P, et al. Hepatic antipyrine metabolism in malnourished patients: influence of the type of malnutrition and course after nutritional rehabilitation. Am J Clin Nutr 1985; 41: 1257-64
81. Juan D, Worwag EM, Schoeller DA, et al. Effects of dietary protein on theophylline pharmacokinetics and caffeine and aminopyrine breath tests. Clin Pharmacol Ther 1986; 40: 187-94
82. Feldman CH, Hulchinson VE, Pippenger CE, et al. Effect of dietary protein and carbohydrate on theophylline metabolism in children. Pediatrics 1980; 66: 956-62
83. Anderson KE, McCleery RB, Vesell ES, et al. Diet and cimetidine induce comparable changes in theophylline metabolism in normal subjects. Hepatology 1991; 13: 941-6
84. Sangrador G, Sánchez-Alcaraz A, Ubeda R, et al. Theophylline plasma clearance in critically ill geriatric patients receiving total parenteral nutrition and in control patients. J Clin Pharm Ther 1990; 15: 273-8
85. Balabaud C, Vinon G, Paccalin J. Influence of dietary protein and carbohydrate on phenytoin metabolism in man. Br J Clin Pharmacol 1979; 8: 369-71
86. Messahel FM, Solis GL, Aguwa CN. Does total parenteral nutrition lower serum phenytoin levels? Curr Ther Res 1990; 47: 1017-20
87. Fraser HS, Mucklow JC, Bulpitt CJ, et al. Environmental effects on antipyrine halt life in man. Clin Pharmacol Ther 1977; 22: 799-805
88. Mucklow JC, Caraher MT, Henderson DB, et al. The effect of individual dietary constituents on antipyrine clearance in Asian immigrants. Br J Clin Pharmacol 1979; 7: 416P-7P
89. Mucklow JC, Rawlins MD, Brodie MJ, et al. Drug oxidation in Asian vegetarians. Lancet 1980; 11: 151
90. Brodie MJ, Boobis AR, Toverud EL, et al. Drug metabolism in white vegetarians. Br J Clin Pharmacol 1980; 9: 523-5
91. Sommers DK, Staden van DA, Moncrieff J, et al. Antipyrine metabolism in African villagers. Human Toxicol 1985; 4: 379-84
92. Mucklow JC, Caraher MT, Idle JR, et al. The influence of changes in dietary fat on the clearance of antipyrine and 4-hydroxylation of debrisoquine. Br J Clin Pharmacol 1980; 9: 283P
93. Tan KKC, Trull AK, Uttridge JA, et al. Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients. Clin Pharmacol Ther 1995; 57: 425-33
94. Yiamouyiannis CA, Harris A, Sanders RA, et al. Paracetamol pharmacokinetics are independent of caloric intake and physical activity. Drug Invest 1994; 8: 361-8
95. Pantuck EJ, Pantuck CB, Kappas A, et al. Effects of protein and carbohydrate content of diet on drug conjugation. Clin Pharmacol Ther 1991; 50: 254-8
96. Krishnaswamy K. Effects of malnutrition on drug metabolism and toxicity in humans. In: Hathcock JN, editor. Nutritional toxicology. Vol. 2. Orlando (FL): Academic Press, Inc. 1987: 105-28
97. Mehta S. Malnutrition and drugs: clinical implications. Dev Pharmacol Ther 1990; 15: 159-65
98. Buchanan N, Davis M, Danhof M, et al. Antipyrine metabolite formation in children in the acute phase of malnutrition and after recovery. Br J Clin Pharmacol 1980; 10: 363-8
99. Lares-Asseff I, Cravioto J, Santiago P, et al. Pharmacokinetics of metronidazole in severely malnourished and nutritionally rehabilitated children. Clin Pharmacol Ther 1992; 51: 42-50
100. Ashton M, Bolme P, Zerihun G, et al. Disposition of salicylic acid in malnourished Ethiopian children after single oral dose. Clin Pharmacokinet 1993; 25: 483-94
101. Treluyer JM, Sultan E, Alexandre JA, et al. Pharmacocinétique de l'aspirine chez l'enfant africain normonutri et malnutri. Arch Fr Pediatr 1991; 48: 337-41
102. O'Shea D, Davis SN, Kim RB, et al. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994; 56: 359-67
103. Garattini S, Ghezzi P, D'Incalci M. Effects of cancer disease on the metabolism of anticancer agents. Pharmac Ther 1988; 37: 57-65
104. Relling MV, Crom WR, Pieper JA, et al. Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy. Clin Pharmacol Ther 1987; 41: 651-60
105. Fleming RA, Milano GA, Etienne M-C, et al. No effect of dose, hepatic function, or nutritional status of 5-FU clearance following continuous (5-day), 5-FU infusion. Br J Cancer 1992; 66: 668-72
106. Conney AH, Pantuck EJ, Kuntzman R, et al. Nutrition and chemical biotransformation in man. Clin Pharmacol Ther 1977; 22: 707-19
107. Pantuck EJ, Pantuck CB, Garland WA, et al. Stimulatory effect of Brussels sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther 1979; 25: 88-95
108. Wattenberg LW. Inhibitors of chemical carcinogens. J Environ Pathol Toxicol 1980; 3: 35-52
109. Wattenberg LW, Loub WD. Inhibition of polycyclic aromatic hydrocarbon-induced neoplasia by naturally-occurring indoles. Cancer Res 1978; 1410-3
110. Hoensch HP, Steinhardt HJ, Weiss G, et al. Effects of semisynthetic diets on xenobiotic metabolizing enzyme activity and morphology of small intestinal mucosa in humans. Gastroenterology 1984; 86: 1519-30
111. Pantuck EJ, Pantuck CB, Anderson KE, et al. Effect of Brussels sprouts and cabbage on drug conjugation. Clin Pharmacol Ther 1984; 35: 161-9
112. McDanell RE, Henderson LA, Russell K, et al. The effect of brassica vegetable consumption on caffeine metabolism in humans. Hum Exp Toxicol 1992; 11: 167-72
113. Kim RB, Wilkinson GR. Watercress inhibits human CYP2E1 activity in vivo as measured by chlorzoxazone 6-hydroxylation. Clin Pharmacol Ther 1996; 59: 170
114. Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268-9
115. Bailey DG, Arnold JMO, Munoz C, et al. Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther 1993; 53: 637-42
116. Edgar B, Bailey D, Bergstrand R, et al. Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine - and its potential clinical relevance. Eur J Clin Pharmacol 1992; 42: 313-7
117. Soons PA, Vogels BAPM, Roosemalen MCM, et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther 1991; 50: 394-403
118. Kupferschmidt HHT, Ha HR, Ziegler WH, et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58: 20-8
119. Hukkinen SK, Varhe A, Olkkola KT, et al. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 1995; 58: 127-31
120. Merkel U, Sigusch H, Hoffmann A. Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers. Eur J Clin Pharmacol 1994; 46: 175-7
121. Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP 1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol 1993; 35: 431-6
122. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995; 57: 485-91
123. Hollander AAMJ, Rooij van J, Lentjes EGWM, et al. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther 1995; 57: 318-24
124. Bailey DG, Arnold JMO, Spence JD. Grapefruit juice and drugs: how significant is the interaction? Clin Pharmacokinet 1994; 26: 91-8
125. Hansson I, Sillanpaa M. Pyridoxine and serum concentration of phenytoin and phenobarbitone. Lancet 1976; I: 256
126. Duvoisin RC, Yahr MD, Cotè LD. Pyridoxine reversal of L-DOPA effects in parkinsonism. Trans Am Neurol Assoc 1969; 94: 81-4
127. Hsu TH, Bianchine JR, Preziosi TJ, et al. Effect of pyridoxine on levodopa metabolism in normal and parkinsonian patients. Proc Soc Exp Biol NY 1973; 143: 578-81
128. Furlanut M, Benetello P, Avogaro A, et al. Effects of folic acid on phenytoin kinetics in healthy subjects. Clin Pharmacol Ther 1978; 24: 295-7
129. Baylis EM, Crowley JM, Preece JM, et al. Influence of folic acid on blood phenytoin levels. Lancet 1971; I: 62-4
130. Maxwell JD, Hunter J, Stewart DA, et al. Folate deficiency after anticonvulsant drugs: an effect of hepatic enzyme induction. BMJ 1972; I: 297-9
131. Houston JB, Levy G. Modification of drug biotransformation by vitamin C in man. Nature 1975; 255: 78-9
132. Back DJ, Bates M, Breckenridge AM, et al. Drug metabolism by the gastrointestinal mucosa: clinical aspects. In: Prescott LF, Nimmo WS, editors. Drug absorption. Lancaster: MTP Press Limited, 1981: 80-6
133. Back DJ, Breckenridge AM, MacIver M, et al. The gut wall metabolism of ethinyloestradiol and its contribution to the pre-systemic metabolism of ethinyloestradiol in humans. Br J Clin Pharmacol 1982; 13: 325-30
134. Orme ML'E, Back DJ, Breckenridge AM. Clinical pharmacokinetics of oral contraceptive steroids. Clin Pharmacokinet 1983; 8: 95-136
135. Back DJ, Breckenridge AM, Maclver M, et al. Interaction of ethinyloestradiol with ascorbic acid in man. BMJ 1981; 282: 1516
136. Briggs MH. Megadose vitamin C and metabolic effects of the pill. BMJ 1981; 283: 1547
137. Dunne JW, Davidson L, Vandongen R, et al. The effect of ascorbic acid on the sulfate conjugation of ingested noradrenaline and dopamine. Br J Clin Pharmacol 1984; 17: 356-60
138. Houston JB. Effect of vitamin C supplement on antipyrine disposition in man. Br J Clin Pharmacol 1977; 4: 236-9
139. Kempin SJ. Warfarin resistance caused by broccoli. N Engl J Med 1983; 308: 1229-30
140. Qureshi GD, Reinders TP, Swint JJ, et al. Acquired warfarin resistance and weight-reducing diet. Arch Intern Med 1981; 141: 507-9
141. Walker FB. Myocardial infarction after diet-induced warfarin resistance. Arch Intern Med 1984; 144: 2089-90
142. Kaminsky LS, Dunbar DA, Wang PP, et al. Human hepatic cytochrome P-450 compositions as probed by in vitro microsomal metabolism of warfarin. Drug Metab Disposit 1984; 12: 470-7
143. Reiter S, Löffler W, Gröbner W, et al. Influence of dietary purines on the metabolism of allopurinol in man. World Rev Nutr Diet 1984; 43: 187-91
144. Dennis MJ, Massey RC, McWeeny DJ, et al. Analysis of polycyclic aromatic hydrocarbons in UK total diets. Food Chem Toxicol 1983; 21: 569-74
145. Grimmer G, Hildebrandt A. Kohlenwasserstoffe in der Umgebung des Menschen: II. Mitteilung: Der Gehalt polycyclischer Kohlenwasserstoffe in Brotgetreide verschiedener Standorte. Z Krebsforsch 1965; 67: 272-7
146. Larsson BK. Polycyclic aromatic hydrocarbons in smoked fish. Z Lebensm Unters Forsch 1982; 174: 101-7
147. Santodonato J, Howard P, Dasu D. Health and ecological assessment of polynuclear aromatic hydrocarbons. J Environ Pathol Toxicol 1981; 5: 1-364
148. Conney AH, Pantuck EJ, Hsiao KC, et al. Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef. Clin Pharmacol Ther 1976; 20: 633-42
149. Pantuck EJ, Hsiao KC, Conney AH, et al. Effect of charcoal-broiled beef on phenacetin metabolism in man. Science 1976; 194: 1055-7
150. Kappas A, Alvarez AP, Anderson KE, et al. Effects of charcoal-broiled beet on anlipyrine and theophylline metabolism. Clin Pharmacol Ther 1978; 23: 445-50
151. Anderson KE, Schneider J, Pantuck EJ, et al. Acetaminophen metabolism in subjects fed charcoal-broiled beef. Clin Pharmacol Ther 1983; 34: 369-74
152. LaDu B. Effects of GRAS substances on pharmacologic effects of drugs. Clin Pharmacol Ther 1977; 22: 743-7
153. Daniel JW. Metabolic aspects of antioxidants and preservatives. Xenobiotica 1986; 16: 1073-8
154. Verhagen H, Beckers HHG, Comuth WV, et al. Disposition of single oral doses of butylated hydroxytoluene in man and rat. Food Chem Toxicol 1989; 27: 765-72
155. Verhagen H, Maas LM, Beekers RHG, et al. Effect of subacute oral intake of the food antioxidant butylated hydroxyanisole on clinical parameters and phase-I and -II biotransformation capacity in man. Human Toxicol 1989; 8: 451-9